Syros Pharmaceuticals, Inc. Common Stock
SYRS
SYRS was delisted on the 19th of March, 2025.
49 hedge funds and large institutions have $251M invested in Syros Pharmaceuticals, Inc. Common Stock in 2017 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 26 increasing their positions, 7 reducing their positions, and 4 closing their positions.
271% more repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 7
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
100% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 4
22% more capital invested
Capital invested by funds: $205M → $251M (+$45.8M)
9% more funds holding
Funds holding: 45 → 49 (+4)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$15.6M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$6.57M |
| 3 |
BBA
Baker Bros. Advisors
New York
|
+$5.82M |
| 4 |
BlackRock
New York
|
+$5.74M |
| 5 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$4.66M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$5.44M |
| 2 |
Alyeska Investment Group
Chicago,
Illinois
|
-$1.81M |
| 3 |
EC
EcoR1 Capital
San Francisco,
California
|
-$1.01M |
| 4 |
Millennium Management
New York
|
-$186K |
| 5 |
JP Morgan Chase
New York
|
-$178K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$9.11K | -58 | -97% |
|
|
TRCT
52
Tower Research Capital (TRC)
New York
| – | -$1K | -5 | Closed |
|
53
Barclays
London,
United Kingdom
| – | -$157 | -1 | -50% |
|
SYRS Hedge Fund Activity: Q2 2017 in Review
49 of the 4,012 institutional investors tracked by Wall St. Rank reported a position in Syros Pharmaceuticals, Inc. Common Stock (SYRS) for Q2 2017, worth a combined $251M — up 22% from $205M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new SYRS positions and 4 closed out — a net gain of 4 holders — while 26 added to existing stakes and 7 trimmed.
The largest buyer was Wellington Management Group, opening a new position worth an estimated $15.6M. The largest seller was Deerfield Management, cutting an estimated $5.44M.
- 49 institutional investors held Syros Pharmaceuticals, Inc. Common Stock (SYRS) as of Q2 2017, up from 45 in Q1 2017.
- Funds reported $251M of Syros Pharmaceuticals, Inc. Common Stock stock for Q2 2017, up 22% quarter-over-quarter.
- 8 funds opened new Syros Pharmaceuticals, Inc. Common Stock positions in Q2 2017 and 4 closed out, a net change of +4 holders.
- The largest Syros Pharmaceuticals, Inc. Common Stock buyer in Q2 2017 was Wellington Management Group, an estimated $15.6M added.
- The largest Syros Pharmaceuticals, Inc. Common Stock seller in Q2 2017 was Deerfield Management, an estimated $5.44M sold.
Based on aggregated 13F filings for Q2 2017.